Home fda approves
 

Keywords :   


Tag: fda approves

FDA Approves Mercks GRASTEK (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Children and Adults

2014-04-14 23:59:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. GRASTEK is the Only FDA Approved Sublingual Allergy Immunotherapy Tablet Indicated for Children as Young as 5 Years of Age WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved GRASTEK (Timothy Grass Pollen Allergen Extract) Tablet for Sublingual Use [2800 Bioequivalent Allergy Units (BAU)]. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: without children adults treat

 

U.S. FDA approves Celgene drug for psoriatic arthritis

2014-03-22 01:04:03| Biotech - Topix.net

U.S. health regulators on Friday approved a Celgene Corp drug to treat psoriatic arthritis, a type of arthritis associated with the skin disease psoriasis that causes joint pain, stiffness and swelling.

Tags: drug arthritis fda approves

 
 

FDA Approves Merck's NOXAFIL (posaconazole) Injection (18 mg/mL) for Intravenous Use

2014-03-15 04:54:54| Biotech - Topix.net

Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL injection , a new formulation of NOXAFIL for intravenous use.

Tags: use injection fda approves

 

FDA Approves Mercks NOXAFIL (posaconazole) Injection (18 mg/mL) for Intravenous Use

2014-03-14 18:40:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use. Mercks antifungal agent is also marketed as NOXAFIL (100 mg) delayed-release tablets and NOXAFIL (40 mg/mL) oral suspension. Language: English Contact: MerckMedia:Pam Eisele, (267) 305-3558Robert Consalvo, (908) 423-6595orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: use injection fda approves

 

FDA approves Bristol-Myers drug for rare body fat disorder

2014-02-25 20:20:03| Biotech - Topix.net

Bristol-Myers Squibb Co said the U.S. Food and Drug Administration approved its drug to treat rare and potentially fatal disorders involving loss of body fat.

Tags: body drug rare fat

 

Sites : [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] next »